Spectrum Pharmaceuticals, Inc. Scoops Up Allos Therapeutics, Inc. in Deal Worth $206 Million as Bladder Cancer Drug Fails Phase 3

Published: Apr 06, 2012

(Reuters) - Spectrum Pharmaceuticals Inc (SPPI.O) said its experimental drug to treat bladder cancer failed to meet the main goals of late-stage trials, sending its shares down 16 percent in premarket trade.

The company was testing the drug apaziquone in two late-stage trials for non-muscle invasive bladder tumors.

The company also said it agreed to buy Allos Therapeutics (ALTH.O) for about $206 million.

Back to news